Apart from the FDA complete response letter, Dasynoc’s launch hinges on litigation around patents for crystalline forms of dasatinib, the generic name for BMS’ Sprycel. Regarding the intellectual property litigation, Xspray has said it’s “confident” those dasatinib presentations don’t occur in...